← Leaderboards
Ulysses J Magalang
University Of Pennsylvania
$2,923,633
Attributed
$4,444,548
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,444,548 · 3
CDC$0 · 1
By mechanism
R01$3,041,830 · 2
P01$1,402,718 · 1
R25$0 · 1
Top collaborators
- Narasimham Laxmi Parinandi4 shared
- Allan Ian Pack2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Allan Ian Pack$56,782,953
- Haresh Kirpalani$3,942,476
- Nalaka S Gooneratne$12,307,702
- Jayaram K Udupa$10,486,434
- Indira Gurubhagavatula$1,638,777
Others in their field
Top investigators on “Sleep”
- Chanza Baytop · Westat, Inc.$271,217,917
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Stanley Carlton Ahalt · Univ Of North Carolina Chapel Hill$78,409,067
- Michael W Weiner · Northern California Institute Res &Educ$71,598,372
- Susan S Redline · Brigham And Women'S Hospital$70,983,879
- Richard Gibbs · Baylor College Of Medicine$68,573,551
Research focus
SleepCardiovascular Risk FactorAffectObstructive Sleep ApneaSleep DisordersHypoxiaProteinsCardiovascular DiseasesRisk FactorsMedicineContinuous Positive Airway PressureSleep DisturbancesStructureSleeplessnessSleep Apnea SyndromesSymptomsReportingPersonsDrowsinessComorbidityPositive Airway PressureSamplingValidationHuman Subject
Grant awards (10)
Undiagnosed Obstructive Sleep Apnea in Primary Care Clinics$794,859
R01 · FY2025 · HL · contact PI
MicroRNAs as Biomarkers for Obstructive Sleep Apnea$454,778
P01 · FY2025 · HL · contact PI
Undiagnosed Obstructive Sleep Apnea in Primary Care Clinics$740,271
R01 · FY2024 · HL · contact PI
MicroRNAs as Biomarkers for Obstructive Sleep Apnea$451,657
P01 · FY2024 · HL · contact PI
MicroRNAs as Biomarkers for Obstructive Sleep Apnea$496,283
P01 · FY2023 · HL · contact PI
Intermittent hypoxia, adiponectin, and insulin resistance in cardiovascular risk$362,950
R01 · FY2013 · HL
Intermittent hypoxia, adiponectin, and insulin resistance in cardiovascular risk$381,250
R01 · FY2012 · HL
Intermittent hypoxia, adiponectin, and insulin resistance in cardiovascular risk$381,250
R01 · FY2011 · HL
Intermittent hypoxia, adiponectin, and insulin resistance in cardiovascular risk$381,250
R01 · FY2010 · HL
Sleep Education in Western New York$0
R25 · FY2002 · OH